Regeneron is the most productive antibody discovery company in biopharmaceutical history and one of the world's leading biotechnology companies.
Regeneron generated $14.3 billion in revenue in 2025, growing approximately 1% year-over-year, with its commercial portfolio anchored by Dupixent (dupilumab) — the world's best-selling immunology drug with over $14 billion in net sales in 2025 across atopic dermatitis, asthma, COPD, eosinophilic esophagitis, prurigo nodularis, and allergic rhinitis. Regeneron's VelocImmune platform has generated more FDA-approved fully human antibody therapies than any other discovery platform in history, including Dupixent, Eylea (aflibercept), Kevzara, Praluent, Inmazeb, and Libtayo. The company's collaboration with Sanofi — which funds Dupixent development and commercialization — is the most commercially successful biopharmaceutical partnership in industry history.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Technological Know-How and Key Products
7. M&A and Partnerships
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Regeneron — Key Financial Metrics 2023-2025
Table 2. Regeneron — Revenue by Product 2023-2025
Table 3. Regeneron — Revenue by Geography 2023-2025
Table 4. Regeneron — R&D Investment 2023-2025
Table 5. Regeneron — SWOT Analysis
Table 6. Regeneron — Key Products and Pipeline 2025
Table 7. Regeneron — M&A Activity 2020-2025
Table 8. Regeneron — Key Management 2025
Table 9. Regeneron — Strategic Priorities 2025-2030
